Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.05%87.301.3%$1275.26m
AMGNAmgen Inc.
-0.25%198.891.2%$667.61m
GILDGilead Sciences, Inc.
-1.28%67.640.9%$577.79m
BIIBBiogen Inc.
-1.63%332.031.3%$485.41m
LOXOLoxo Oncology Inc
-0.18%233.2612.7%$449.60m
ILMNIllumina, Inc.
0.05%305.633.5%$350.96m
VRTXVertex Pharmaceuticals Incorporated
-0.28%186.151.9%$318.23m
REGNRegeneron Pharmaceuticals, Inc.
-0.12%404.542.6%$308.69m
ALXNAlexion Pharmaceuticals, Inc.
-0.03%111.702.0%$229.47m
TSROTESARO, Inc.
0.03%74.8814.4%$201.67m
AAgilent Technologies, Inc.
-0.82%70.021.5%$164.25m
EXASExact Sciences Corporation
-2.75%74.9725.3%$151.07m
INCYIncyte Corporation
-2.79%76.562.5%$146.84m
SRPTSarepta Therapeutics, Inc.
0.45%119.2615.4%$142.24m
LGNDLigand Pharmaceuticals Incorporated
-16.48%110.0523.1%$105.44m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products includes CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.